Retinitis pigmentosa gene therapy - ID Pharma/Kyushu University

Drug Profile

Retinitis pigmentosa gene therapy - ID Pharma/Kyushu University

Alternative Names: DVC1-0401

Latest Information Update: 08 Jul 2016

Price : $50

At a glance

  • Originator ID Pharma; Kyushu University
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Retinitis pigmentosa

Most Recent Events

  • 08 Jul 2016 Clinical development is ongoing in Japan
  • 26 Mar 2013 Clinical trials in Retinitis pigmentosa in Japan (unspecified route)
  • 10 Nov 2010 Investigation in Retinitis pigmentosa in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top